Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/08/548   
Active ingredient: Carfilzomib
Indication: Treatment of multiple myeloma
Sponsor: Amgen Europe B.V.
Minervum 7061, 4817 ZK Breda, Nederland
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Kyprolis on 19/11/2015 with the number EU/1/15/1060

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/06/2008 Orphan designation EMEA/OD/120/07 (2008)2534 of 03/06/2008
07/10/2008 Transfer of orphan designation EMEA/OD/120/07/T/01 (2008)5753 of 03/10/2008
15/10/2009 Change of name and/or address of sponsor EMEA/OD/120/07
18/10/2012 Change of name and/or address of sponsor EMEA/OD/120/07
06/11/2012 Transfer of orphan designation EMEA/OD/120/07/T/02 (2012)7994 of 31/10/2012
23/06/2014 Transfer of orphan designation EMA/OD/120/07/T/03 (2014)4242 of 19/06/2014
08/10/2015 Other procedure